Rezolute, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RZLT research report →
Range $6 – $14
Price Chart
About the company
Rezolute, Inc. , a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for the treatment of hypoglycemia; and clinical trials of ersodetug for tumor hyperinsulinism.
- CEO
- Nevan Charles Elam
- IPO
- 2013
- Employees
- 63
- HQ
- Redwood City, CA, US
Get TickerSpark's AI analysis on RZLT
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $379.18M
- P/E
- -5.16
- Fwd P/E
- 17.04
- PEG
- -0.26
- P/S
- 0.00
- P/B
- 4.78
- EV/EBITDA
- -4.65
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -72.24%
- ROIC
- -94.66%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-82,966,000
- Net Income
- $-77,586,000-4.3%
- EPS
- $-0.75+23.5%
- OCF Growth
- +6.4%
- FCF Growth
- +6.4%
- 52W High
- $11.17
- 52W Low
- $1.07
- 50D MA
- $4.05
- 200D MA
- $3.94
- Beta
- 0.62
- RSI (14)
- 48
- Avg Volume
- 1.73M
No earnings-call transcripts are available for RZLT yet.
- Free Float
- 68.8%
- Shares Outstanding
- 96.73M
- Float Shares
- 66.59M
of shares held by institutions
152 13F filers
Buy/sell ratio 1.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Federated Hermes, Inc. | 12.95M | ▼ 42.14K |
| Ra Capital Management, L.P. | 9.45M | 0 |
| Blackrock, Inc. | 8.27M | ▲ 553.44K |
| Jennison Associates LLC | 5.33M | ▲ 2.87M |
| Vanguard Group Inc | 4.79M | ▲ 378.43K |
| Opaleye Management Inc. | 4.09M | ▼ 2.21M |
| Balyasny Asset Management L.P. | 3.77M | ▼ 896.16K |
| Vanguard Capital Management LLC | 3.72M | ▼ 117.51K |
| Siren, L.L.C. | 3.33M | 0 |
| D. E. Shaw & Co., Inc. | 2.39M | ▲ 549.58K |
| Geode Capital Management, LLC | 2.13M | ▼ 36.63K |
| State Street Corp | 1.83M | ▼ 21.00K |
Held by 146 ETFs
Biggest fund positions in RZLT by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 21, 26 | Evans Daron | other | 16,000 |
| Oct 21, 26 | Evans Daron | other | 4,000 |
| Sep 2, 26 | Karnawat Sunil Ratilal | other | 2,267 |
| Jul 2, 26 | ROBERTS BRIAN KENNETH | other | 3,062 |
| Jul 2, 26 | Elam Nevan C | other | 8,004 |
| Jul 2, 26 | Evans Daron | other | 3,062 |
| Mar 30, 26 | Evans Daron | buy | 10,000 |
| Mar 2, 26 | ROBERTS BRIAN KENNETH | other | 11,439 |
| Mar 2, 26 | Evans Daron | other | 11,438 |
| Mar 2, 26 | Elam Nevan C | other | 27,618 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our RZLT coverage
Recent articles, reports, and earnings notes.
No research on RZLT yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate RZLT report →Rezolute Raises $100 Million, Advances Ersodetug Toward Commercialization
benzinga.com · Nov 13
Rezolute Announces Pricing of Approximately $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
globenewswire.com · Nov 13
Rezolute Announces Positive Results from the Phase 3 upLIFT Study in Tumor Hyperinsulinism
globenewswire.com · Nov 13
Rezolute Reports First Quarter Fiscal 2027 Financial Results and Provides Business Update
globenewswire.com · Nov 5
Rezolute (NASDAQ:RZLT) Share Price Breaks Above 200 Day Moving Average – Here’s What Happened
defenseworld.net · Nov 4
Rezolute to Participate in Upcoming Investor Conferences
globenewswire.com · Nov 2
Rezolute (NASDAQ:RZLT) Stock Price Crosses Below 200-Day Moving Average – What’s Next?
defenseworld.net · Oct 27
Rezolute Announces Completion of Enrollment in Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism
globenewswire.com · Oct 14
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.